Theodore Nicolaides, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Theodore Nicolaides, MD

Assistant Professor, Department of Pediatrics (Hematology/Oncology), UCSF

Phone: (415) 476-3831 (appts)
UCSF Box 0106, San Francisco, CA 94143-0106

UCSF Profiles | Physician Referral Directory

Cancer Center Membership

Program Member » Neurologic Oncology» Pediatric Malignancies

Education

Northwestern University, Evanston, IL, B.A., 1993-1997, Biology
New York University, New York, NY, M.D., 1997-2001, Medicine


Professional Experience

  • 2001-2004
    Pediatrics Residency, New York University
  • 2004-2007
    Pediatric Hematology/Oncology Fellowship at University of California San Francisco
  • 2008-2009
    Clinical Instructor, Pediatrics, University of California San Francisco

Honors & Awards

  • 2006-2008
    NIH Extramural Loan Repayment Program Award for Research in Pediatrics
  • 2007-2009
    American Brain Tumor Association Research Fellowship
  • 2009-2010
    California Institute of Regenerative Medicine Training Grant
  • 2009-2011
    AACR-Aflac Pediatric Cancer Research Career Development Award
  • 2009-2011
    Alex's Lemonade Stand Foundation Young Investigator Award

Selected Publications

  1. Zhang J, Yao TW, Hashizume R, Hariono S, Barkovich KJ, Fan QW, Prados M, James CD, Weiss WA, Nicolaides T. Combined BRAF(V600E) and MEK blockade for BRAF(V600E)-mutant gliomas. J Neurooncol. 2016 Nov 15.
    View on PubMed
  2. Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget. 2016 Oct 3.
    View on PubMed
  3. Wadhwa E, Nicolaides T. Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. Cureus. 2016; 8(5):e620.
    View on PubMed
  4. Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA. Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol. 2016 Feb; 126(3):395.
    View on PubMed
  5. Lerner RG, Grossauer S, Kadkhodaei B, Meyers I, Sidorov M, Koeck K, Hashizume R, Ozawa T, Phillips JJ, Berger MS, Nicolaides T, James CD, Petritsch CK. Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. Cancer Res. 2015 Dec 15; 75(24):5355-66.
    View on PubMed
  6. Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, David James C, Mueller S, Haas-Kogan DA. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol. 2016 Feb; 126(3):385-93.
    View on PubMed
  7. Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015 Sep 8; 6(26):21993-2005.
    View on PubMed
  8. Truong AY, Nicolaides TP. Targeted Therapy for MAPK Alterations in Pediatric Gliomas. Brain Disord Ther. 2015 Aug; Suppl 2.
    View on PubMed
  9. Barajas RF, Phelps A, Foster HC, Courtier J, Buelow BD, Gupta N, Nicolaides T, Glenn OA, Banerjee A. Metastatic Diffuse Intrinsic Pontine Glioma to the Peritoneal Cavity Via Ventriculoperitoneal Shunt: Case Report and Literature Review. J Neurol Surg Rep. 2015 Jul; 76(1):e91-6.
    View on PubMed
  10. Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Mol Cancer Ther. 2014 Dec; 13(12):2919-29.
    View on PubMed
  11. Schoenfeld A, Haas-Kogan DA, Molinaro A, Banerjee A, Nicolaides T, Tihan T, Bollen AW, Gupta N, Mueller S. Pure germinomas of the central nervous system: treatment strategies and outcomes. J Neurooncol. 2014 Dec; 120(3):643-9.
    View on PubMed
  12. Cage TA, Samagh SP, Mueller S, Nicolaides T, Haas-Kogan D, Prados M, Banerjee A, Auguste KI, Gupta N. Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Childs Nerv Syst. 2013 Aug; 29(8):1313-9.
    View on PubMed
  13. Hashizume R, Smirnov I, Liu S, Phillips JJ, Hyer J, McKnight TR, Wendland M, Prados M, Banerjee A, Nicolaides T, Mueller S, James CD, Gupta N. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. J Neurooncol. 2012 Dec; 110(3):305-13.
    View on PubMed
  14. Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A. 2012 May 29; 109(22):8710-5.
    View on PubMed
  15. See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res. 2012 Jul 1; 72(13):3350-9.
    View on PubMed
  16. Barkovich KJ, Hariono S, Garske AL, Zhang J, Blair JA, Fan QW, Shokat KM, Nicolaides T, Weiss WA. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov. 2012 May; 2(5):450-7.
    View on PubMed
  17. Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman TA, James CD. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res. 2011 Dec 15; 17(24):7595-604.
    View on PubMed
  18. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal. 2010; 3(147):ra81.
    View on PubMed
  19. Yoon DJ, Kwan BH, Chao FC, Nicolaides TP, Phillips JJ, Lam GY, Mason AB, Weiss WA, Kamei DT. Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery. Cancer Res. 2010 Jun 1; 70(11):4520-7.
    View on PubMed
  20. Nicolaides T, Tihan T, Horn B, Biegel J, Prados M, Banerjee A. High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system. J Neurooncol. 2010 May; 98(1):117-23.
    View on PubMed

Go to UCSF Profiles, powered by CTSI